tradingkey.logo

Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial

ReutersFeb 3, 2026 1:21 PM

- Pfizer Inc PFE.N:

  • PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL

  • PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL

  • PFIZER - STUDY SHOWS 12.3% WEIGHT LOSS AT WEEK 28

  • PFIZER - 10 PHASE 3 TRIALS WITH PF’3944 EXPECTED IN 2026

  • PFIZER - STUDY MET PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT WEIGHT REDUCTION AT 28 WEEKS WITH A COMPETITIVE TOLERABILITY PROFILE

  • PFIZER - PF’3944 MAINTAINS FAVORABLE SAFETY PROFILE THROUGH WEEK 28

  • PFIZER - PLANNING AN EXPANSIVE OBESITY DEVELOPMENT PROGRAM ACROSS ITS PIPELINE, WITH PLANS TO ADVANCE 20+ TRIALS IN 2026

  • PFIZER: ACROSS ARMS 1 AND 3, FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO ADVERSE EVENTS IN WEEKLY PHASE

  • PFIZER: ACROSS ARMS 1 AND 3 FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO AES IN MONTHLY PHASE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI